Ascendis Pharma A/S (ASND) has a consensus analyst rating of Buy, based on 24 analysts covering the stock. Of those, 22 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for ASND is $287.17, representing a +14.9% upside from the current price of $249.84. Price targets range from a low of $250.00 to a high of $342.00.
